Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Lik Sprava ; (5-6): 182-5, 2001.
Article in Ukrainian | MEDLINE | ID: mdl-11881370

ABSTRACT

In the article, errors that are frequently encountered in dealing with rheumatic diseases are analysed together with the experience gained by the authors themselves with the management of 380 patients using local injections of corticosteroids (diprospan) and chondroprotectors (alflutop). The employment of local injection therapy has been shown to shorten considerably the patient's hospital stay, to improve the quality of life of the patients, with them being practically free from ill effects and complications.


Subject(s)
Betamethasone/analogs & derivatives , Rheumatic Diseases/drug therapy , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/therapeutic use , Betamethasone/administration & dosage , Betamethasone/therapeutic use , Drug Administration Schedule , Drug Combinations , Female , Humans , Injections, Subcutaneous , Male , Protective Agents/administration & dosage , Protective Agents/therapeutic use , Retrospective Studies , Triamcinolone Acetonide/administration & dosage , Triamcinolone Acetonide/therapeutic use
2.
Ter Arkh ; 71(1): 31-4, 1999.
Article in Russian | MEDLINE | ID: mdl-10097297

ABSTRACT

AIM: Assessment of efficiency and safety of enalapril (enap) and its combination with hydrochlorotiaside (enap-N). MATERIALS AND METHODS: 127 patients with mild and moderate blood hypertension entered an open non-comparative multicenter trial. 60 of them received enap (group 1), 67--enap N (group 2). Group 1 patients were given enap for 2 weeks in a dose 10 mg/day. If this dose was not adequate to normalize blood pressure, it was raised to 20-40 mg/day. Patients of group 2 received enap-N one tablet a day for 3 weeks. If the pressure persisted higher than 140/90 mm Hg, the treatment was continued for 3 weeks more in a dose of 2 tablets a day. RESULTS: Blood pressure lowered under 140/90 mm Hg in 40 patients of group 1 (66.7%). Systolic pressure dropped by 10 mm Hg minimum and diastolic by 5 mm minimum in 18 group 1 patients (30%). Enap-N reduced blood pressure under 140-90 mm Hg in 44 of 67 patients (65.7%). Systolic and diastolic pressure dropped, respectively, in 23(34.3%) patients. CONCLUSION: Enap and enap-N tablets were found highly effective and well tolerated. Side effects were caused by lowering of blood pressure.


Subject(s)
Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Enalapril/therapeutic use , Hypertension/drug therapy , Administration, Oral , Adolescent , Adult , Angiotensin-Converting Enzyme Inhibitors/administration & dosage , Blood Pressure/drug effects , Diuretics , Drug Therapy, Combination , Enalapril/administration & dosage , Follow-Up Studies , Humans , Hydrochlorothiazide/administration & dosage , Hydrochlorothiazide/therapeutic use , Hypertension/diagnosis , Hypertension/physiopathology , Middle Aged , Safety , Severity of Illness Index , Sodium Chloride Symporter Inhibitors/administration & dosage , Sodium Chloride Symporter Inhibitors/therapeutic use , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...